SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (126)	9/6/2000 10:14:37 PM
From: Jim Oravetz	Read Replies (1) of 164

It is estimated that 3.5 million people suffer C. difficile infections annually in North America and in 20% of these infections (700,000 cases) the condition can progress to severely recurrent CDAD. This condition is thought to affect approximately 1.65 million people a year in North America, Japan and Europe. Most of these cases occur in hospitals, causing extended patient stays and greater health care costs. There is presently no suitable treatment for the recurrent form as the bacterium forms robust spores that are resistant to conventional antibiotics. There is therefore intense interest among clinicians and patients in novel, effective, and safe treatments to help with C. difficile disease control. smallcapsonline.com From WORD document under SYBBF. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next